Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: STLA stock price vs MRK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRK's multiple
Needs MRK P/S.
Implied fair value · at STLA's multiple
Needs STLA P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: STLA FY 2025 (ended Dec 31, 2025) · MRK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Stellantis N.V. · implied price per share
Bear
-$57.01
Base
-$67.07
Bull
-$77.13
Merck & Co., Inc. · implied price per share
Bear
$84.04
Base
$98.87
Bull
$113.70
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
0.48x
Net debt / EBITDA
Leverage against operating earnings
—
0.34x
Cash and equivalents
Liquid reserves on the balance sheet
$30.15B
$15.01B
Total debt
Interest-bearing obligations outstanding
—
$25.10B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
FORD MOTOR CO
STLA vs F
General Motors Co
STLA vs GM
Tesla, Inc.
STLA vs TSLA
Rivian Automotive, Inc. / DE
STLA vs RIVN
Lucid Group, Inc.
STLA vs LCID
Pfizer Inc.
STLA vs PFE
Johnson & Johnson
STLA vs JNJ
Eli Lilly and Company
STLA vs LLY
Bristol-Myers Squibb Company
STLA vs BMY
AbbVie Inc.
STLA vs ABBV
AMGEN INC
STLA vs AMGN
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe STLA can materially reverse its negative margins and loss-making profile, then consider the stock only as a turnaround situation because the current implied valuation is not supported by the reported earnings and quality metrics.
The valuation gap is extreme: STLA trades at $5.81 versus an implied price of $299.65 on the provided P/S basis, suggesting more than 50x upside, but this is inconsistent with the underlying fundamentals. The historical band of $5.23 to $6.39 places STLA near the upper end of its recent trading range, so the stock is not cheaply priced relative to its own history despite the headline implied upside.
Supporting Metrics
